Work

Inhibitors of PARP: Number crunching and structure gazing

Year: 2022

Type: article

Abstract: Significance PARP is an important target in the treatment of cancers, particularly in patients with breast, ovarian, or prostate cancer that have compromised homologous recombination repair (i.e., BRCA −/− ). This review about inhibitors of PARP (PARPi) is for readers interested in the development of next-generation drugs for the treatment of cancer, providing insights into structure–activity relationships, in vitro vs. in vivo potency, PARP trapping, and synthetic lethality.

Source: Proceedings of the National Academy of Sciences

DOI: 10.1073/pnas.2121979119

Authors: Johannes Rudolph, Karen Jung, Karolin Luger

Institution: University of Colorado Boulder

Language: English

Topic: PARP inhibition in cancer therapy

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: hybrid

Funders: Howard Hughes Medical Institute, National Cancer Institute